Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM).

Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM). ESMO 2018

Oral Presentation